KR20150040355A - 피페리디늄 4급 염들 - Google Patents

피페리디늄 4급 염들 Download PDF

Info

Publication number
KR20150040355A
KR20150040355A KR20157006047A KR20157006047A KR20150040355A KR 20150040355 A KR20150040355 A KR 20150040355A KR 20157006047 A KR20157006047 A KR 20157006047A KR 20157006047 A KR20157006047 A KR 20157006047A KR 20150040355 A KR20150040355 A KR 20150040355A
Authority
KR
South Korea
Prior art keywords
methyl
piperidinium
acetoxy
diphenyl
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157006047A
Other languages
English (en)
Korean (ko)
Inventor
캐슬린 이. 클라렌스-스미스
토마스 엔. 체이스
Original Assignee
체이스 파마슈티칼스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체이스 파마슈티칼스 코포레이션 filed Critical 체이스 파마슈티칼스 코포레이션
Publication of KR20150040355A publication Critical patent/KR20150040355A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
KR20157006047A 2012-08-09 2013-07-30 피페리디늄 4급 염들 Ceased KR20150040355A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
US61/681,415 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005139A Division KR102240999B1 (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Publications (1)

Publication Number Publication Date
KR20150040355A true KR20150040355A (ko) 2015-04-14

Family

ID=50068488

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20157006047A Ceased KR20150040355A (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들
KR1020207005139A Expired - Fee Related KR102240999B1 (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207005139A Expired - Fee Related KR102240999B1 (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Country Status (14)

Country Link
US (1) US9896416B2 (https=)
EP (1) EP2882711B1 (https=)
JP (1) JP6345665B2 (https=)
KR (2) KR20150040355A (https=)
CN (2) CN104603108A (https=)
AU (1) AU2013300009B2 (https=)
BR (1) BR112015002832B1 (https=)
CA (1) CA2881182C (https=)
EA (1) EA029678B9 (https=)
HK (1) HK1211572A1 (https=)
IL (1) IL236996A0 (https=)
IN (1) IN2015DN01018A (https=)
MX (1) MX356386B (https=)
WO (1) WO2014025569A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
KR102791527B1 (ko) 2019-08-22 2025-04-03 오피노 엘엘씨 다중 액세스에 대한 정책 제어
CN117018194B (zh) * 2023-07-26 2026-04-17 同济大学 毒蕈碱型受体5型受体拮抗剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (https=) * 1973-07-12 1974-06-20
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
DE10129832A1 (de) 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
JP5541863B2 (ja) * 2005-08-12 2014-07-09 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 神経雪崩アッセイ
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
SE0600876L (sv) 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
EP2013172A4 (en) 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
EP2470504B1 (en) * 2010-03-15 2013-10-16 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos

Also Published As

Publication number Publication date
US9896416B2 (en) 2018-02-20
KR20200022522A (ko) 2020-03-03
AU2013300009B2 (en) 2017-06-15
IN2015DN01018A (https=) 2015-06-26
AU2013300009A1 (en) 2015-02-26
HK1211572A1 (en) 2016-05-27
CN108658842A (zh) 2018-10-16
JP2015524469A (ja) 2015-08-24
JP6345665B2 (ja) 2018-06-20
US20150203452A1 (en) 2015-07-23
EA201500209A1 (ru) 2015-05-29
EA029678B9 (ru) 2018-07-31
BR112015002832B1 (pt) 2022-08-16
IL236996A0 (en) 2015-03-31
MX356386B (es) 2018-05-28
BR112015002832A2 (https=) 2017-07-04
CA2881182A1 (en) 2014-02-13
CN104603108A (zh) 2015-05-06
CA2881182C (en) 2021-01-26
EA029678B1 (ru) 2018-04-30
EP2882711A1 (en) 2015-06-17
MX2015001769A (es) 2015-05-08
EP2882711B1 (en) 2017-10-25
EP2882711A4 (en) 2016-02-10
KR102240999B1 (ko) 2021-04-15
WO2014025569A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US8568699B2 (en) Soft anticholinergic zwitterions
DE69623799T2 (de) Kondensierte tropanderivate als neurotransmitter-reuptake-inhibitoren
CA2807082C (en) Crystalline form of pyrimido[6,1-a]isoquinolin-4-one compound
RU2193557C2 (ru) Бензоциклогептатиофеновые соединения, способы профилактики или лечения, фармацевтическая композиция
KR102240999B1 (ko) 피페리디늄 4급 염들
CA2112084C (en) Antidepressant and antiparkinsonian compounds
EP2083007B1 (de) Tiotropiumsalze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittelformulierungen
AU2006315657B2 (en) Soft anticholinergic esters
JPH09510222A (ja) ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
WO2014063587A1 (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
CN115141229A (zh) 抗组胺类化合物及其制备方法和用途
TW200836732A (en) Novel compounds
WO2003066599A1 (de) N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine und ihre verwendung als arzneimittel
HK1166310B (en) Nalmefene hydrochloride dihydrate
HK1166310A (en) Nalmefene hydrochloride dihydrate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180724

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190821

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200221

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200225

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I